IL17A and temporal arteritis: The TiTAIN trial proved that treatment with secukinumab (an IL-17 inhibitor) is a safe and efficient choice in patients with new onset or relapsing GCA naïve to biological therapy.24 Regarding the JAK inhibitors in GCA, based on the results of SELECT-GCA trial which showed positive results, their use is recommended by EMA in patients over 65 years only if no suitable treatment alternatives are available.